semaglutide patent expiry europe Ozempic, Wegovy and Rybelsus: The patents behind Novo Nordisk's weight-loss drugs Today marks the day when

At the same time, both Lilly and Novo Nordisk made multi-billion dollar capital investments in expanding their manufacturing capacity to satisfy unrelenting patient demand, including pharmas largest M&A deal of the year, the $16.5Bn acquisition of CDMO Catalent by Novo Holdings, the controlling shareholder of Novo Nordisk

Hundreds of patients have reported experiencing severe side effects, including Ozempic vomiting

Trials and Performance

Of note is that T2D and obesity, by ...

Welcome to TODAY'S AJENDA!

GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) act on the brain as well as the gut, and a 2026 real-world cohort study from Kamel-Abusalha et a